Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068029 · ClinicalTrials.gov registry record · Phase 4
Pegvisomant And Sandostatin LAR Combination Study
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
NCT00068029: Completed Phase 4 study, sponsored by Pfizer.
NCT00068029 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 75 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00068029, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
Interventions
- DRUG Pegvisomant
- DRUG Sandostatin LAR
- DRUG Pegvisomant/ Sandostatin LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
What the finished NCT00068029 record still lists
NCT00068029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 3 interventions - of which Pegvisomant is the first listed.
NCT00068029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00068029 about?
NCT00068029 is a clinical study titled "Pegvisomant And Sandostatin LAR Combination Study". The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
What is the current status of trial NCT00068029?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2003-10. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00068029?
The interventions under investigation include: Pegvisomant (DRUG), Sandostatin LAR (DRUG), Pegvisomant/ Sandostatin LAR (DRUG).
Who is sponsoring clinical trial NCT00068029?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00068029's enrollment target sits among peer trials
75 1002nd of 2000 higher than 974 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia